• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Isodiol International Inc. Appoints Beverage Industry Veteran, Kevin Swadish, to a Newly Created Position as Chief Revenue Officer

    Anwesha Sengupta
    Feb. 14, 2019 06:39AM PST
    Cannabis Investing News
    CSE:ISOL

    Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) announces the appointment of beverage industry executive Kevin Swadish to the newly created C-level position of Chief Revenue Officer of Isodiol. 

    Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) announces the appointment of beverage industry executive Kevin Swadish to the newly created C-level position of Chief Revenue Officer of Isodiol.  This position will oversee the revenue strategies for all of Isodiol’s Consumer Packaged Goods (CPG) operations, including beverages, skin care and related cosmetics, and over-the-counter products.

    “We are very pleased to welcome Kevin to our team at Isodiol,” said Marcos Agramont, CEO of Isodiol.  “The Company has made a number of hard choices in the restructuring of its business model and staffing in recent months to embrace its core competencies, exit non-performing operations, divest non-performing assets, and adapt to a rapidly developing industry.  These are all experiences that Kevin has addressed and overcome in his storied tenure in the beverage industry, and we look forward to leveraging his experiences and relationships to achieve a dominant position in emerging CPG retail opportunities.”

    Mr. Swadish has served in a variety of executive leadership roles in both mass market and specialty beverage sectors throughout the United States and developed a network of relationships that include the nation’s largest distributors and retailers.  He started his career with E. & J. Gallo, which is the leading wine company in the US and considered a top training ground for industry professionals1. During his 12 years with Gallo, he assumed increasing responsibilities, including sales management of the San Diego market and as Southwest Division Manager of the company’s distributors.

    Subsequently, Mr. Swadish held senior management roles at various leading wine and spirits companies. He was Senior Vice President of sales and marketing for Young’s Market Company, which is one of the largest beverage alcohol distributors in the United States2.  Mr. Swadish also served as Chief Operating Officer of Skyy Vodka, which was one of the largest brand introductions in the history of the U.S. spirits industry. In addition to serving as an executive of established brands, Mr. Swadish ventured into entrepreneurship and successfully formed and exited various ventures.

    Mr. Swadish received his BA degree from Long Beach State University in California.

    Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.

    About Isodiol International Inc.

    Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018.  Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

    ON BEHALF OF THE BOARD

    Marcos Agramont, CEO & Director

    INVESTOR RELATIONS:

    Ir@isodiol.com
    604-409-4409

    MEDIA CONTACT:

    Christopher Hussey
    media@isodiol.com

    Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

    The CSE has not reviewed, approved or disapproved the content of this press release.

    1 https://www.bloomberg.com/research/stocks/private/person.asp?personId=9185758&privcapId=9174223

    2 https://www.youngsmarket.com/about/

    Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation. 

    Source: globenewswire.ca

    isodiol international inc.cannabis investingcse:isol
    The Conversation (0)
    Go Deeper
    AI Powered
    CSE:ISOL

    Isodiol International Inc. Increases Size of Non-Brokered Offering and Retains Clarus Securities as Financial Advisor

    CSE:ISOL

    Isodiol International Inc. Provides Update on Biosynthesis Pharma Group Acquistion

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×